Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T15:03:08.766Z.
Calculation as of: 2026-10-06T15:03:08.766Z.
Quote observation: 2026-10-06T15:00:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84870b41b004d4a356f3546a7a12828ec10b1f950fc42869db9e2e4c5d55c05b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Immix Biopharma, Inc.
Market Cap
$538.51M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$537.47M
Free Cash Flow Yield
3.26%
TTM Avg
3.62%
3Y Avg
3.23%
5Y Avg
3.23%
Market Cap
$550.03M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$537.29M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$552.54M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$521.19M
Free Cash Flow Yield
N/A
TTM Avg
536.25%
3Y Avg
536.25%
5Y Avg
536.25%
Market Cap
$561.45M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$560.00M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$514.49M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $538.51M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $537.47M | 3.26% | 3.62% | 3.23% | 3.23% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $550.03M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $537.29M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.54M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $521.19M | N/A | 536.25% | 536.25% | 536.25% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $561.45M | N/A | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $514.49M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $514.07M | 0.09% | 0.12% | 0.12% | 0.12% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
